title: [Clinical efficacy of Z-100 for the treatment of leukopenia caused by radiotherapy--a multi-center double-blind comparative study with L-cysteine].
abstract: The clinical usefulness of Z-100 (Z group) for the treatment of leukopenia caused by radiotherapy for malignant tumors was evaluated by comparing it with that of L-cysteine (L group) by the double-blind method. For 178 complete cases, there were no significant differences in the time-course of the WBC during radiotherapy between the two group. However, for cases with a large field of irradiation (15 X 15 cm = 225 cm2), the mean WBC count in the L group decreased more than that in the Z group. The Z group showed comparable or superior efficacy for the treatment of leukopenia in the L group although there were no significant differences. Adverse reactions were observed in 5.66% and 2.94% in the Z and L groups, respectively, without any significant difference between the groups. The utility rate, useful or better, was 73.9% and 69.2% in the Z and L groups, respectively, showing a slightly higher rate in the Z group than in the L group, although the difference between the two groups was not significant. These results confirmed that Z-100 has comparable or superior efficacy to L-cysteine for the treatment of leukopenia caused by large field radiotherapy for malignant tumors.
authors.affiliation: Department of Radiology, Keio University School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
authors.forename: T
authors.initials: T
authors.lastname: Ohkawa
authors.forename: Y
authors.initials: Y
authors.lastname: Takekawa
authors.forename: J
authors.initials: J
authors.lastname: Horiuchi
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: S
authors.initials: S
authors.lastname: Amino
authors.forename: K
authors.initials: K
authors.lastname: Morita
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Mochizuki
authors.forename: T
authors.initials: T
authors.lastname: Yanagisawa
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003545:Cysteine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007564:Japan; D007970:Leukopenia / Q000188:drug therapy* / Q000209:etiology; D008055:Lipids / Q000627:therapeutic use*; D008297:Male; D008351:Mannans / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy; D011878:Radiotherapy / Q000009:adverse effects*
chemical_list: D000276:Adjuvants, Immunologic; D008055:Lipids; D008351:Mannans; C031208:specific substance maruyama; D003545:Cysteine